Article Text

Download PDFPDF
Complementary Prognostic Value of Pelvic Magnetic Resonance Imaging and Whole-Body Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Pretreatment Assessment of Patients With Cervical Cancer
  1. Evis Sala, MD, PhD*,
  2. Maura Micco, MD*,
  3. Irene A. Burger, MD*,
  4. Derya Yakar, MD*,
  5. Marisa A. Kollmeier, MD,
  6. Debra A. Goldman, MS,
  7. Mithat Gonen, PhD,
  8. Kay J. Park, MD§,
  9. Nadeem R. Abu-Rustum, MD,
  10. Hedvig Hricak, MD, PhD* and
  11. Hebert Alberto Vargas, MD*
  1. *Departments of Radiology,
  2. Departments of Radiation Oncology,
  3. Departments of Epidemiology-Biostatistics,
  4. §Departments of Pathology, and
  5. Departments of Surgery, Gynecologic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY.
  1. Address correspondence and reprint requests to Evis Sala, MD, PhD, Department of Radiology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10065. E-mail:


Objective The aim of this study was to evaluate the incremental prognostic value of pelvic magnetic resonance imaging (MRI) and whole-body 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) findings compared with clinical-histopathologic factors in patients with newly diagnosed cervical cancer.

Methods The institutional review board approved this retrospective study of 114 patients (median age, 40.6 years) with International Federation of Gynecology and Obstetrics (FIGO) stage I-IVB cervical cancer who underwent pretreatment MRI and PET/CT. All scans were reviewed for locoregional tumor extent, pelvic or/and para-aortic lymphadenopathy, and distant metastases. Univariate Cox proportional hazard regression was performed to evaluate associations between clinical-histopathologic factors, imaging findings, and progression-free survival (PFS). Multivariate models were built using independent predictors for PFS. Harrell C was used to measure concordance (C index).

Results Forty patients progressed within a median time of 10.4 months (range, 0.4–40.3 months). At univariate analysis, age, FIGO stage, tumor histology, tumor grade, and all MRI and PET/CT features were significantly associated with PFS (P < 0.0001 to P = 0.0474). A multivariate model including clinical and imaging parameters (parametrial invasion on MRI and para-aortic lymphadenopathy/distant metastases on PET/CT) had significantly higher concordance for predicting PFS than a model including clinical parameters only (C index: 0.81 [95% confidence interval, 0.75–0.87] vs 0.68 [95% confidence interval, 0.59–0.78]; P < 0.001). The comparison of C indices for the combined clinical and imaging model approached significance when compared with a FIGO stage model (C index: 0.81 [95% confidence interval, 0.75–0.87] vs 0.75 [95% confidence interval, 0.69–0.82]; P = 0.058).

Conclusions In patients with newly diagnosed cervical cancer, a prognostic model including combined MRI and PET/CT findings provides information that complements clinical and histopathologic factors.

  • Prognostic value
  • Pelvic MRI
  • Whole-body FDG PET/CT
  • Cervical cancer

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • The authors declare no conflicts of interest.